Molecular mechanisms mediating metastasis of hypoxic breast cancer cells

Vaupel, 2004, Tumor hypoxia and malignant progression, Methods Enzymol., 381, 335, 10.1016/S0076-6879(04)81023-1 Vaupel, 2007, Detection and characterization of tumor hypoxia using pO2 histography, Antioxid. Redox Signal., 9, 1221, 10.1089/ars.2007.1628 Vaupel, 2009, Prognostic potential of the pre-therapeutic tumor oxygenation status, Adv. Exp. Med. Biol., 645, 241, 10.1007/978-0-387-85998-9_36 Wilson, 2011, Targeting hypoxia in cancer therapy, Nat. Rev. Cancer, 11, 393, 10.1038/nrc3064 Semenza, 2012, Hypoxia inducible factors in physiology and medicine, Cell, 148, 399, 10.1016/j.cell.2012.01.021 Wang, 1995, Purification and characterization of hypoxia-inducible factor 1, J. Biol. Chem., 270, 1230, 10.1074/jbc.270.3.1230 Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. U.S.A., 92, 5510, 10.1073/pnas.92.12.5510 Ivan, 2001, HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science, 292, 464, 10.1126/science.1059817 Jaakkola, 2001, Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 Yu, 2001, HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation, Proc. Natl. Acad. Sci. U.S.A., 98, 9630, 10.1073/pnas.181341498 Lando, 2002, Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch, Science, 295, 858, 10.1126/science.1068592 Semenza, 2010, Oxygen homeostasis, Wiley Interdiscip. Rev. Syst. Biol. Med., 2, 336, 10.1002/wsbm.69 Loboda, 2010, HIF-1 and HIF-2 transcription factors – similar but not identical, Mol. Cells, 29, 435, 10.1007/s10059-010-0067-2 Bos, 2003, Levels of hypoxia-inducible factor 1α independently predict prognosis in patients with lymph node negative breast carcinoma, Cancer, 97, 1573, 10.1002/cncr.11246 Schindl, 2002, Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer, Clin. Cancer Res., 8, 1831 Giatromanolaki, 2004, c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1α dependent, Clin. Cancer Res., 10, 7972, 10.1158/1078-0432.CCR-04-1068 Dales, 2005, Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients, Int. J. Cancer, 116, 734, 10.1002/ijc.20984 Vleugel, 2005, Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer, J. Clin. Pathol., 58, 172, 10.1136/jcp.2004.019885 Generali, 2006, Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer, Clin. Cancer Res., 12, 4562, 10.1158/1078-0432.CCR-05-2690 Kronblad, 2006, Hypoxia-inducible factor 1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response, Int. J. Cancer, 118, 2609, 10.1002/ijc.21676 Trastour, 2007, HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome, Int. J. Cancer, 120, 1451, 10.1002/ijc.22436 Yamamoto, 2008, Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer, Breast Cancer Res. Treat., 110, 465, 10.1007/s10549-007-9742-1 Bos, 2001, Levels of hypoxia-inducible factor 1α during breast carcinogenesis, J. Natl. Cancer Inst., 93, 309, 10.1093/jnci/93.4.309 Helczynska, 2008, Hypoxia-inducible factor 2α correlates to distant recurrence and poor outcome in invasive breast cancer, Cancer Res., 68, 9212, 10.1158/0008-5472.CAN-08-1135 Buffa, 2010, Large meta-analysis of multiple cancers reveals a common, compact, and highly prognostic hypoxia metagene, Br. J. Cancer, 102, 428, 10.1038/sj.bjc.6605450 Talmadge, 2010, AACR centennial series: the biology of cancer metastasis: historical perspective, Cancer Res., 70, 5649, 10.1158/0008-5472.CAN-10-1040 Weigelt, 2005, Breast cancer metastasis; markers and models, Nat. Rev. Cancer, 5, 591, 10.1038/nrc1670 Fidler, 1970, Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2′-deoxyuridine, J. Natl. Cancer Inst., 45, 773 Minn, 2005, Genes that mediate breast cancer metastasis to lung, Nature, 436, 518, 10.1038/nature03799 Gupta, 2007, Mediators of vascular remodeling co-opted for sequential steps in lung metastasis, Nature, 446, 765, 10.1038/nature05760 Liao, 2007, Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression, Cancer Res., 67, 563, 10.1158/0008-5472.CAN-06-2701 Cailleau, 1974, Breast tumor cell lines from pleural effusions, J. Natl. Cancer Inst., 53, 661, 10.1093/jnci/53.3.661 Jordan, 2007, Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer, Steroids, 72, 7, 10.1016/j.steroids.2006.10.009 Shepard, 2008, Herceptin, Handb. Exp. Pharmacol., 181, 183, 10.1007/978-3-540-73259-4_9 Hudis, 2011, Triple-negative breast cancer: an unmet medical need, Oncologist, 16, 1, 10.1634/theoncologist.2011-S1-01 Zhang, 2012, HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs, Oncogene, 31, 1757, 10.1038/onc.2011.365 Sullivan, 2007, Hypoxia-driven selection of the metastatic phenotype, Cancer Metastasis Rev., 26, 319, 10.1007/s10555-007-9062-2 Padua, 2008, TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4, Cell, 133, 66, 10.1016/j.cell.2008.01.046 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Erler, 2006, Lysyl oxidase is essential for hypoxia-induced metastasis, Nature, 440, 1222, 10.1038/nature04695 Erler, 2009, Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche, Cancer Cell, 15, 35, 10.1016/j.ccr.2008.11.012 Wong, 2011, Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation, Proc. Natl. Acad. Sci. U.S.A., 108, 16369, 10.1073/pnas.1113483108 Chambers, 2009, MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?, Cancer Res., 69, 5292, 10.1158/0008-5472.CAN-09-1528 Zhang, 2008, Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth, Proc. Natl. Acad. Sci. U.S.A., 105, 19579, 10.1073/pnas.0809763105 Wong, 2012, Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis, J. Mol. Med., 90, 803, 10.1007/s00109-011-0855-y Kummar, 2011, Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors, Clin. Cancer Res., 17, 5123, 10.1158/1078-0432.CCR-11-0682 Lee, 2009, Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization, Proc. Natl. Acad. Sci. U.S.A., 106, 17910, 10.1073/pnas.0909353106 Lee, 2009, Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells, Proc. Natl. Acad. Sci. U.S.A., 106, 2353, 10.1073/pnas.0812801106 Gao, 2007, HIF-dependent antitumorigenic effect of antioxidants in vivo, Cancer Cell, 12, 230, 10.1016/j.ccr.2007.08.004 Terzuoli, 2010, Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion, Cancer Res., 70, 6837, 10.1158/0008-5472.CAN-10-1075 Kaluz, 2006, Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain, Mol. Cell. Biol., 26, 5895, 10.1128/MCB.00552-06 Kong, 2005, Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity, Cancer Res., 65, 9047, 10.1158/0008-5472.CAN-05-1235 Qian, 2006, Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α, Cancer Res., 66, 8814, 10.1158/0008-5472.CAN-05-4598 Chintala, 2010, Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α, Cancer Chemother. Pharmacol., 66, 899, 10.1007/s00280-009-1238-8 Laughner, 2001, HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, Mol. Cell. Biol., 21, 3995, 10.1128/MCB.21.12.3995-4004.2001 Carbonaro, 2011, Microtubule disruption targets HIF-1α mRNA to cytoplasmic P-bodies for translational repression, J. Cell Biol., 192, 83, 10.1083/jcb.201004145 Liu, 2007, RACK1 competes with HSP90 for binding to HIF-1α and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1α, Mol. Cell, 25, 207, 10.1016/j.molcel.2007.01.001